Type 2 Diabetes and NHS Weight Loss Injections: What Applies to You

Which NHS weight loss injections are actually available if you have type 2 diabetes?

Two injectable GLP-1 medicines are currently available for weight management through private prescribing and, in some circumstances, through the NHS: tirzepatide, sold as Mounjaro, and semaglutide, sold as Wegovy. Both are licensed for adults whose BMI qualifies, with type 2 diabetes counting as one of the weight-related conditions that can lower the eligibility threshold from 30 to 27.

On the NHS, tirzepatide was recommended by NICE in December 2024 (TA1026) for adults with a BMI of 35 or above and at least one weight-related comorbidity. The rollout is phased. From June 2025, those with a BMI of 40 or above and four or more of five qualifying conditions (which include type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea and cardiovascular disease) became eligible. A second cohort covering BMI 35–39.9 with four or more of those conditions was activated in June 2026. Further cohorts are expected from around March 2027. You can read the full NICE appraisal of tirzepatide (TA1026) for the exact recommendation wording.

Semaglutide (Wegovy) sits under a separate NICE recommendation, TA875, and is accessed via specialist weight management services for a maximum of two years. For many people with type 2 diabetes, the practical reality is a long wait or a referral that does not yet meet local thresholds, and our page on weight loss injections on the NHS for people with diabetes covers exactly how this plays out in practice. An overview of how NHS weight loss injections work sets out the broader landscape if you want to understand the full pathway.

Does having type 2 diabetes change which medicines a prescriber might consider?

Yes, in several important ways. Type 2 diabetes means you may already be taking medicines that interact with GLP-1 therapies, in particular, insulin and sulphonylureas carry a risk of hypoglycaemia when combined with tirzepatide or semaglutide, because both the diabetes medicines and the GLP-1 agent lower blood glucose. A prescriber will typically review your current diabetes regimen before starting a weight management injection, and adjustments to insulin dose in particular are common. This is not a reason to avoid treatment; it is a reason to have a thorough clinical assessment.

Tirzepatide acts on both GIP and GLP-1 receptors, which gives it a dual mechanism that can be particularly relevant for people managing blood sugar alongside weight. Semaglutide targets GLP-1 receptors only. Both have been studied in people with type 2 diabetes (SURMOUNT-2 examined tirzepatide specifically in this population) and both produced meaningful reductions in body weight alongside improvements in glycaemic markers. The NHS patient information for tirzepatide covers the key interactions and conditions to discuss with a prescriber.

If you are taking Ozempic for diabetes management, it is worth knowing that Ozempic and Wegovy are both semaglutide, but they are prescribed under different licences for different clinical purposes. Switching, combining or adjusting doses is a clinical decision, not something to attempt independently. Our page on diabetic injections for weight loss on the NHS goes into this distinction in more detail.

What if you don't meet NHS criteria yet, or simply can't wait?

This is the situation a lot of people find themselves in. The NHS phasing means that even with type 2 diabetes and a qualifying BMI, you may fall outside the current cohort, live in an area where GP practices have not yet opted into the new prescribing contract, or face a long wait for a specialist referral, and our guide to getting a weight loss injection on the NHS explains the referral process and what to expect at each stage. None of that changes whether you are clinically suitable for treatment; it only changes whether the NHS will fund it right now.

Private prescribing through a regulated online pharmacy offers an alternative for people who have had a clinical assessment and been found suitable. At nume, every consultation is read personally by a GPhC-registered Independent Prescriber on the same day, your answers are not processed by an algorithm. If approved, treatment is dispatched the same working day for free next-working-day delivery. You can explore our weight loss treatment options to start a free consultation.

One practical note on cost: private treatment is funded by the patient, and medicines in this class are not inexpensive. A realistic overview of how much weight loss injections cost in the UK private market is worth reading before you decide. The right question is not just affordability but whether the service you are accessing is genuinely clinically supervised and sourcing from the licensed UK supply chain.

Are there situations where these medicines are not suitable, even with type 2 diabetes?

Several. People who are pregnant, breastfeeding or actively trying to conceive should not use tirzepatide or semaglutide, the guidance is clear that these medicines are not recommended in any of those circumstances, and a prescriber will not approve them. Women of childbearing age who start tirzepatide and use oral contraceptives need to add a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide can reduce oral contraceptive absorption. If you are wondering whether any of the newer weight loss injections becoming available on the NHS change these restrictions, the answer is that the same contraindications apply across the class. This is covered in NHS England's guidance on weight management injections.

A personal or family history of medullary thyroid carcinoma or MEN2, active or recent pancreatitis, and certain gastrointestinal conditions are among the factors a prescriber will ask about directly. If you have had a pancreas-related diagnosis, be clear about it during your consultation. The MHRA's Yellow Card scheme is where patients and clinicians can report suspected side effects, including any unexpected symptoms once treatment has started.

People under 18 are not eligible, neither medicine is licensed for this age group. Beyond these specific exclusions, suitability is individual; a prescriber considers your full health history, current medicines and circumstances before making any decision. Our frequently asked questions address some of the common eligibility queries in plain language.